Adarsh Malgave , Sideequl Akbar , Anumol Joseph , Dande Aishwarya , Ramalingam Peraman , Rajkumar Malayandi
{"title":"pH、缓冲液、摩尔浓度和温度对用LC-HRMS降解西马鲁肽溶液状态的影响:肽药物递送的预配制方案","authors":"Adarsh Malgave , Sideequl Akbar , Anumol Joseph , Dande Aishwarya , Ramalingam Peraman , Rajkumar Malayandi","doi":"10.1016/j.ejpb.2025.114780","DOIUrl":null,"url":null,"abstract":"<div><div>Semaglutide (SGL), a long-acting GLP-1 (Glucagon-like peptide) receptor agonist, is a 31-amino acid peptide modified with a C18 fatty diacid for albumin binding. Peptides are fragile and susceptible to degradation during formulation, storage, and transportation. The degradation of peptides resulted in the formation of impurities that may impact safety, efficacy, immunogenicity, and regulatory compliance. The present study examines the effects of pH, temperature, buffer species, and molarity on the stability of SGL. Reverse-phase ultra-performance liquid chromatography (RP-UPLC) was used to separate impurities, followed by liquid chromatography high-resolution mass spectrometry (LC-HRMS) for their molecular weight. The stress stability studies were conducted in thermal stress conditions at 25 °C, 40 °C, 60 °C (for 28 days), and 80 °C (for 7 days). The influence of pH, buffer strength, and buffer species on the degradation of SGL was investigated at 25 °C and 40 °C. The degradation of SGL resulted in thirteen known impurities, and their fragments were identified using LC-MS analysis. Six impurities, such as impurity 4 (<em>m</em>/<em>z</em> = 2717.21), impurity 5 (<em>m</em>/<em>z</em> = 4129.64), impurity 7 (<em>m</em>/<em>z</em> = 3762.28), impurity 8 (<em>m</em>/<em>z</em> = 3456.94), impurity 12 (<em>m</em>/<em>z</em> = 2967.5), and impurity 13 (<em>m</em>/<em>z</em> = 839), were formed across all the testing conditions. These impurities were relatively stable when compared to other formed impurities. The influence of pH on the thermal stability of SGL was demonstrated. The impurities, such as impurity 2 (<em>m</em>/<em>z</em> = 845.13), impurity 9 (<em>m</em>/<em>z</em> = 3397.76), impurity 10 (<em>m</em>/<em>z</em> = 701.0), and impurity 11 (<em>m</em>/<em>z</em> = 4125.7), were absent across all pH conditions, but these impurities were found when water was used as a solvent. The study demonstrated that the pH was a key factor for the thermal degradation of SGL. The degradation pathways were elucidated based on the mass data for known masses. The solution-state thermal stress studies were performed to select the buffer for formulating long-acting PLGA formulations. Moreover, the solution state stress stability data could be helpful for optimization of the pharmaceutical process, in vivo stability of SGL in muscles, storage and transportation of finished products, and determining the shelf-life.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"214 ","pages":"Article 114780"},"PeriodicalIF":4.3000,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery\",\"authors\":\"Adarsh Malgave , Sideequl Akbar , Anumol Joseph , Dande Aishwarya , Ramalingam Peraman , Rajkumar Malayandi\",\"doi\":\"10.1016/j.ejpb.2025.114780\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Semaglutide (SGL), a long-acting GLP-1 (Glucagon-like peptide) receptor agonist, is a 31-amino acid peptide modified with a C18 fatty diacid for albumin binding. Peptides are fragile and susceptible to degradation during formulation, storage, and transportation. The degradation of peptides resulted in the formation of impurities that may impact safety, efficacy, immunogenicity, and regulatory compliance. The present study examines the effects of pH, temperature, buffer species, and molarity on the stability of SGL. Reverse-phase ultra-performance liquid chromatography (RP-UPLC) was used to separate impurities, followed by liquid chromatography high-resolution mass spectrometry (LC-HRMS) for their molecular weight. The stress stability studies were conducted in thermal stress conditions at 25 °C, 40 °C, 60 °C (for 28 days), and 80 °C (for 7 days). The influence of pH, buffer strength, and buffer species on the degradation of SGL was investigated at 25 °C and 40 °C. The degradation of SGL resulted in thirteen known impurities, and their fragments were identified using LC-MS analysis. Six impurities, such as impurity 4 (<em>m</em>/<em>z</em> = 2717.21), impurity 5 (<em>m</em>/<em>z</em> = 4129.64), impurity 7 (<em>m</em>/<em>z</em> = 3762.28), impurity 8 (<em>m</em>/<em>z</em> = 3456.94), impurity 12 (<em>m</em>/<em>z</em> = 2967.5), and impurity 13 (<em>m</em>/<em>z</em> = 839), were formed across all the testing conditions. These impurities were relatively stable when compared to other formed impurities. The influence of pH on the thermal stability of SGL was demonstrated. The impurities, such as impurity 2 (<em>m</em>/<em>z</em> = 845.13), impurity 9 (<em>m</em>/<em>z</em> = 3397.76), impurity 10 (<em>m</em>/<em>z</em> = 701.0), and impurity 11 (<em>m</em>/<em>z</em> = 4125.7), were absent across all pH conditions, but these impurities were found when water was used as a solvent. The study demonstrated that the pH was a key factor for the thermal degradation of SGL. The degradation pathways were elucidated based on the mass data for known masses. The solution-state thermal stress studies were performed to select the buffer for formulating long-acting PLGA formulations. Moreover, the solution state stress stability data could be helpful for optimization of the pharmaceutical process, in vivo stability of SGL in muscles, storage and transportation of finished products, and determining the shelf-life.</div></div>\",\"PeriodicalId\":12024,\"journal\":{\"name\":\"European Journal of Pharmaceutics and Biopharmaceutics\",\"volume\":\"214 \",\"pages\":\"Article 114780\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-06-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Pharmaceutics and Biopharmaceutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0939641125001572\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutics and Biopharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0939641125001572","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery
Semaglutide (SGL), a long-acting GLP-1 (Glucagon-like peptide) receptor agonist, is a 31-amino acid peptide modified with a C18 fatty diacid for albumin binding. Peptides are fragile and susceptible to degradation during formulation, storage, and transportation. The degradation of peptides resulted in the formation of impurities that may impact safety, efficacy, immunogenicity, and regulatory compliance. The present study examines the effects of pH, temperature, buffer species, and molarity on the stability of SGL. Reverse-phase ultra-performance liquid chromatography (RP-UPLC) was used to separate impurities, followed by liquid chromatography high-resolution mass spectrometry (LC-HRMS) for their molecular weight. The stress stability studies were conducted in thermal stress conditions at 25 °C, 40 °C, 60 °C (for 28 days), and 80 °C (for 7 days). The influence of pH, buffer strength, and buffer species on the degradation of SGL was investigated at 25 °C and 40 °C. The degradation of SGL resulted in thirteen known impurities, and their fragments were identified using LC-MS analysis. Six impurities, such as impurity 4 (m/z = 2717.21), impurity 5 (m/z = 4129.64), impurity 7 (m/z = 3762.28), impurity 8 (m/z = 3456.94), impurity 12 (m/z = 2967.5), and impurity 13 (m/z = 839), were formed across all the testing conditions. These impurities were relatively stable when compared to other formed impurities. The influence of pH on the thermal stability of SGL was demonstrated. The impurities, such as impurity 2 (m/z = 845.13), impurity 9 (m/z = 3397.76), impurity 10 (m/z = 701.0), and impurity 11 (m/z = 4125.7), were absent across all pH conditions, but these impurities were found when water was used as a solvent. The study demonstrated that the pH was a key factor for the thermal degradation of SGL. The degradation pathways were elucidated based on the mass data for known masses. The solution-state thermal stress studies were performed to select the buffer for formulating long-acting PLGA formulations. Moreover, the solution state stress stability data could be helpful for optimization of the pharmaceutical process, in vivo stability of SGL in muscles, storage and transportation of finished products, and determining the shelf-life.
期刊介绍:
The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics.
Topics covered include for example:
Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids)
Aspects of manufacturing process design
Biomedical aspects of drug product design
Strategies and formulations for controlled drug transport across biological barriers
Physicochemical aspects of drug product development
Novel excipients for drug product design
Drug delivery and controlled release systems for systemic and local applications
Nanomaterials for therapeutic and diagnostic purposes
Advanced therapy medicinal products
Medical devices supporting a distinct pharmacological effect.